This article was originally published in The Gray Sheet
Submits an amendment to its June 1997 premarket approval application for use of its Prep sample preparation system in cervical cancer screening. The amendment follows a request by FDA for more information, including additional analysis and presentation of existing clinical data, to demonstrate sensitivity to low grade, high grade, and cancerous lesions, the firm states. A "small nonclinical internal study" also was included in the amendment. The PMA will not need to be reviewed by an agency advisory panel ("The Gray Sheet" July 14, 1997, p. 8)...
You may also be interested in...
As the first emergency use authorization is granted, Pfizer and Moderna stand accused of neglecting poorer nations as wealthy countries snap up early access to COVID-19 vaccines.
By handing out free supplements to the clinically vulnerable, the UK government is effectively endorsing the use of vitamin D to reduce the risk and/or severity of COVID-19, although it says more research is needed.
A few months after bringing AstraZeneca onboard as a partner, the turnaround at the Alderley Park-based firm is moving ahead, buoyed by a fresh financing.